BioPharmX Corp to Merge with Timber Pharmaceuticals
January 28, 2020
BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.
- Buyers
- BioPharmX Corporation
- Targets
- Timber Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Syros Pharmaceuticals Merges with TYME Technologies
September 16, 2022
Biotechnology
Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.
-
MJH Life Sciences Acquires Pharmaceutical Commerce
July 9, 2020
Media & Entertainment
MJH Life Sciences has acquired Pharmaceutical Commerce, a multimedia B2B publication formerly published by Healthcare Commerce Media Corporation. The acquisition expands MJH’s healthcare media portfolio and strengthens its reach into the biopharma commercial operations and supply-chain audience, adding a magazine with a controlled circulation of roughly 21,000 and multiple newsletters and events.
-
Shionogi Inc. Acquires Qpex Biopharma, Inc.
June 26, 2023
Pharmaceuticals
Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.
-
MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader
July 8, 2024
Pharmaceuticals
MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.
-
Groupe Berkem Acquires i.Bioceuticals from International Nutrition Company (INC)
February 16, 2023
Food & Beverage
Groupe Berkem has acquired i.Bioceuticals, the exclusive North American distributor of OPC and pine bark extracts from Dutch supplier International Nutrition Company (INC). The cash transaction transfers i.Bioceuticals' Massachusetts-based team to Groupe Berkem as the Group expands its bio-based health, beauty and nutraceutical offering and strengthens its footprint in North America.
-
Iptor Acquires TimberTec
February 1, 2022
Software
Stockholm-based Iptor acquired German TimberTec, a provider of ERP and MES software for the timber industry, in a deal that closed in February 2022. The acquisition is an add-on in Iptor's buy-and-build strategy (backed by funds advised by Bregal Unternehmerkapital) and aims to expand Iptor’s sector capabilities and geographic reach across Europe and into the US.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.